E38N interferon gamma polypeptide variants
View Patent ↗A conjugate exhibiting interferon gamma activity and comprising at least one first non-polypeptide moiety covalently linked to an IFG polypeptide, the polypeptide comprising an amino acid sequence that differs from that of a parent IFNG polypeptide in at least one introduced and/or at least one removed amino acid residue comprising an attachment group for the non-polypeptide moiety. The conjugate may be used for treatment of various diseases.
1. An E38N interferon gamma (IFNG) polypeptide variant exhibiting IFNG activity, comprising a polypeptide sequence which (i) differs by 1 to 15 amino acid residues from the wild-type human IFNG sequence shown in SEQ ID NO: 2 or a fragment thereof which is C-terminally truncated by 1 to 15 amino acid residues, and which (ii) comprises the substitution E38N.
2. The variant of claim 1 , further comprising the substitution S40T.
3. The variant of claim 1 , wherein the variant sequence differs by 1 to 8 amino acid residues fi
m the wild-type human IFNG sequence shown in SEQ ID NO: 2 or a fragment thereof which is C-terminally truncated by 1 to 15 amino acid residues.
4. The variant of claim 3 , wherein the variant sequence differs by 1 to 5 amino acid residues from the wild-type human IFNG sequence shown in SEQ ID NO: 2 or a fragment thereof which is C-terminally truncated by 1 to 15 amino acid residues.
5. The variant of claim 1 , wherein the variant is C-terminally truncated by 11 amino acid residues.
6. The variant of claim 1 , wherein the variant is glycosylated.
7. The variant of claim 6 , wherein the variant is glycoslated at N25, N38 and N97.
8. The variant of claim 1 , wherein the variant sequence differs by 3 amino acid residues from the wild-type human IFNG sequence shown in SEQ ID NO: 2 or a fragment thereof which is C-terminally truncated by 1 to 15 amino acid residues.
9. The variant of claim 8 , further comprising the substitution S40T.
10. The variant of claim 9 , wherein the variant is C-terminally truncated by 11 amino acid residues.
11. The variant of claim 10 , wherein the variant is glycosylated.
12. The variant of claim 11 , wherein the variant is glycosylated at N25, N38 and N97.
13. The variant of claim 1 , wherein the variant comprises a cysteine residue, which is introduced into a position of the IFNG polypeptide that in wild-type human IFNG is occupied by a surface-exposed residue.
14. The variant of claim 13 , wherein said introduced cysteine residue is PEGylated.
15. A pharmaceutical composition comprising the E38N interferon gamma polypeptide variant of claim 1 and a pharmaceutically acceptable diluent, carrier or adjuvant.